Microarray analysis of differentially expressed genes in ovarian and fallopian tube epithelium from risk‐reducing salpingo‐oophorectomies

Mutations in the BRCA1 and BRCA2 genes confer an increased lifetime risk for breast and ovarian cancer. Ovarian cancer risk can be decreased by risk‐reducing salpingo‐oophorectomy (RRSO). Studies on RRSO material have altered the paradigm of serous ovarian cancer pathogenesis. The purpose of this study was to identify candidate genes possibly involved in the pathogenesis of serous ovarian cancer by carrying out a microarray analysis of differentially expressed genes in BRCA1/2‐ mutation positive ovarian and fallopian tube epithelium derived from RRSO surgery. Freshly frozen ovarian and fallopian tube samples from nine BRCA1/2 mutation carriers scheduled for RRSO were prospectively collected together with five mutation‐negative control patients undergoing salpingo‐oophorectomy for benign indications. Microarray analysis of genome‐wide gene expression was performed on ovarian and fallopian tube samples from the BRCA1/2 and control patients. The validation of microarray data was performed by quantitative real‐time polymerase chain reaction (qRT‐PCR) in selected cases of RRSO samples and also in high grade serous carcinoma samples collected from patients with a BRCA phenotype. From 22,733 genes, 454 transcripts were identified that were differentially expressed in BRCA1/2 mutation carriers when compared with controls, pooling all ovarian and fallopian tube samples together. Of these, 299 genes were statistically significantly downregulated and 155 genes upregulated. Differentially expressed genes in BRCA1/2 samples reported here might be involved in serous ovarian carcinogenesis and provide interesting targets for further studies. © 2015 Wiley Periodicals, Inc.

[1]  Y. Pommier,et al.  Proteolytic Degradation of Topoisomerase II (Top2) Enables the Processing of Top2·DNA and Top2·RNA Covalent Complexes by Tyrosyl-DNA-Phosphodiesterase 2 (TDP2)* ♦ , 2014, The Journal of Biological Chemistry.

[2]  D. Ribatti,et al.  Aquaporins in cancer. , 2014, Biochimica et biophysica acta.

[3]  T. Tolonen,et al.  Quantitative Analysis of &ggr;-H2AX and p53 Nuclear Expression Levels in Ovarian and Fallopian Tube Epithelium from Risk-reducing Salpingo-Oophorectomies in BRCA1 and BRCA2 Mutation Carriers , 2014, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[4]  Juan Chen,et al.  The Association of Transporter Genes Polymorphisms and Lung Cancer Chemotherapy Response , 2014, PloS one.

[5]  M. Ishikawa,et al.  Endothelial Krüppel-like Factor 4 Regulates Angiogenesis and the Notch Signaling Pathway* , 2014, The Journal of Biological Chemistry.

[6]  M. Pesu,et al.  Therapeutic targeting of the Jak/STAT pathway. , 2014, Basic & clinical pharmacology & toxicology.

[7]  A. Martins Filho,et al.  The immune response in malignant ovarian neoplasms. , 2014, European journal of gynaecological oncology.

[8]  I. Berindan‐Neagoe,et al.  Gene expression profiling reveals activation of the FA/BRCA pathway in advanced squamous cervical cancer with intrinsic resistance and therapy failure , 2014, BMC Cancer.

[9]  Gregory A. Wyant,et al.  Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models. , 2013, Cancer cell.

[10]  K. Xie,et al.  Regulation of EMT by KLF4 in gastrointestinal cancer. , 2013, Current cancer drug targets.

[11]  Marie-Pier Tétreault,et al.  Krüppel-like factors in cancer , 2013, Nature Reviews Cancer.

[12]  E. Jung,et al.  Salt-inducible kinases 1 and 3 negatively regulate Toll-like receptor 4-mediated signal. , 2013, Molecular endocrinology.

[13]  A. Yoshimura,et al.  SOCS, inflammation, and cancer , 2013, JAK-STAT.

[14]  Lei Shen,et al.  Decreased EGR3 expression is related to poor prognosis in patients with gastric cancer , 2013, Journal of Molecular Histology.

[15]  Z. Jia,et al.  Early Growth Response 3 (Egr3) Is Highly Over-Expressed in Non-Relapsing Prostate Cancer but Not in Relapsing Prostate Cancer , 2013, PloS one.

[16]  K. Cibulskis,et al.  Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. , 2012, The Journal of clinical investigation.

[17]  J. George,et al.  Non-equivalent gene expression and copy number alterations in high-grade serous ovarian cancers with BRCA1 and BRCA2 mutations , 2013 .

[18]  Kwangsung Park,et al.  Expression and Localization of Aquaporins in Benign Prostate Hyperplasia and Prostate Cancer , 2012, Chonnam medical journal.

[19]  J. Roh,et al.  Downregulation of KLF4 and the Bcl-2/Bax ratio in advanced epithelial ovarian cancer. , 2012, Oncology letters.

[20]  S. Kjaer,et al.  A binary histologic grading system for ovarian serous carcinoma is an independent prognostic factor: a population-based study of 4317 women diagnosed in Denmark 1978-2006. , 2012, Gynecologic oncology.

[21]  J. Sznajder,et al.  Salt‐inducible kinase 1 regulates E‐cadherin expression and intercellular junction stability , 2012, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[22]  I. Osman,et al.  Roles of Polo-like kinase 3 in suppressing tumor angiogenesis , 2012, Experimental Hematology & Oncology.

[23]  A. D’Andrea,et al.  A DNA Repair Pathway–Focused Score for Prediction of Outcomes in Ovarian Cancer Treated With Platinum-Based Chemotherapy , 2012, Journal of the National Cancer Institute.

[24]  Tatsuhiko Tsunoda,et al.  High-Risk Ovarian Cancer Based on 126-Gene Expression Signature Is Uniquely Characterized by Downregulation of Antigen Presentation Pathway , 2012, Clinical Cancer Research.

[25]  W. Murrell,et al.  Aqp 9 and Brain Tumour Stem Cells , 2012, TheScientificWorldJournal.

[26]  K. Hess,et al.  Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. , 2011, JAMA.

[27]  F. Khuri,et al.  Pleiotropic functions of EAPII/TTRAP/TDP2 , 2011, Cell cycle.

[28]  P. Shaw,et al.  Identification of abrogated pathways in fallopian tube epithelium from BRCA1 mutation carriers , 2011, The Journal of pathology.

[29]  W. McCluggage,et al.  Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis. , 2011, Pathology.

[30]  E. Berns,et al.  Microarray-Based Oncogenic Pathway Profiling in Advanced Serous Papillary Ovarian Carcinoma , 2011, PloS one.

[31]  L. Chodosh,et al.  Krüppel-like factor 4 inhibits tumorigenic progression and metastasis in a mouse model of breast cancer. , 2011, Neoplasia.

[32]  I. Shih,et al.  Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm. , 2011, Human pathology.

[33]  J. Yang,et al.  Expression of Aquaglyceroporins in Epithelial Ovarian Tumours and Their Clinical Significance , 2011, The Journal of international medical research.

[34]  Richard J. Edwards,et al.  SLiMSearch 2.0: biological context for short linear motifs in proteins , 2011, Nucleic Acids Res..

[35]  K. Hess,et al.  Association of BRCA 1 and BRCA 2 Mutations With Survival , Chemotherapy Sensitivity , and Gene Mutator Phenotype in Patients With Ovarian Cancer , 2011 .

[36]  Rochelle L. Garcia,et al.  Identification of a preneoplastic gene expression profile in tubal epithelium of BRCA1 mutation carriers. , 2010, Neoplasia.

[37]  B. Karlan,et al.  Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  Michael L. Gatza,et al.  A pathway-based classification of human breast cancer , 2010, Proceedings of the National Academy of Sciences.

[39]  Matthias Evert,et al.  Oncogenic and tumor suppressive roles of polo‐like kinases in human hepatocellular carcinoma , 2010, Hepatology.

[40]  Ie-Ming Shih,et al.  The Origin and Pathogenesis of Epithelial Ovarian Cancer: A Proposed Unifying Theory , 2010, The American journal of surgical pathology.

[41]  M. Michal,et al.  Smooth muscle/myoid differentiation in uterine tumour resembling ovarian sex‐cord tumour (UTROSCT) , 2009, Histopathology.

[42]  W. Hahn,et al.  SIK1 Couples LKB1 to p53-Dependent Anoikis and Suppresses Metastasis , 2009, Science Signaling.

[43]  C. Crum.  Intercepting pelvic cancer in the distal fallopian tube: Theories and realities , 2009, Molecular oncology.

[44]  P. V. van Diest,et al.  Tubal and ovarian pathways to pelvic epithelial cancer: a pathological perspective , 2009, Histopathology.

[45]  R. Eeles,et al.  "BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  R. Twombly.  Preventive Services Task Force recommends against PSA screening after age 75. , 2008, Journal of the National Cancer Institute.

[47]  Alexander D. Diehl,et al.  Access to immunology through the Gene Ontology , 2008, Immunology.

[48]  B. Rosen,et al.  Gene Expression Profiles of Luteal Phase Fallopian Tube Epithelium from BRCA Mutation Carriers Resemble High-Grade Serous Carcinoma , 2008, Clinical Cancer Research.

[49]  M. Papadopoulos,et al.  Aquaporins—new players in cancer biology , 2008, Journal of Molecular Medicine.

[50]  Wolf-Dietrich Heyer,et al.  Homologous recombination in DNA repair and DNA damage tolerance , 2008, Cell Research.

[51]  R. Barakat,et al.  Risk-reducing salpingo-oophorectomy in patients with germline mutations in BRCA1 or BRCA2. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  R. Drapkin,et al.  Lessons from BRCA: The Tubal Fimbria Emerges as an Origin for Pelvic Serous Cancer , 2007, Clinical Medicine & Research.

[53]  Anil Potti,et al.  An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  Jeffrey T. Chang,et al.  Oncogenic pathway signatures in human cancers as a guide to targeted therapies , 2006, Nature.

[55]  Gordon K. Smyth,et al.  Empirical array quality weights in the analysis of microarray data , 2006, BMC Bioinformatics.

[56]  Crispin J. Miller,et al.  Simpleaffy: a BioConductor package for Affymetrix Quality Control and data analysis , 2005, Bioinform..

[57]  Rongwei Fu,et al.  Genetic Risk Assessment and BRCA Mutation Testing for Breast and Ovarian Cancer Susceptibility: Systematic Evidence Review for the U.S. Preventive Services Task Force , 2005, Annals of Internal Medicine.

[58]  Bart De Moor,et al.  BioMart and Bioconductor: a powerful link between biological databases and microarray data analysis , 2005, Bioinform..

[59]  R. Edlich,et al.  Breast cancer and ovarian cancer genetics. , 2005, Journal of long-term effects of medical implants.

[60]  Jean YH Yang,et al.  Bioconductor: open software development for computational biology and bioinformatics , 2004, Genome Biology.

[61]  Gordon K Smyth,et al.  Statistical Applications in Genetics and Molecular Biology Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray Experiments , 2011 .

[62]  John D. Storey,et al.  Statistical significance for genomewide studies , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[63]  Christos Sotiriou,et al.  Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers. , 2002, Journal of the National Cancer Institute.

[64]  A. Bukovsky,et al.  Immunohistochemical Studies of the Adult Human Ovary: Possible Contribution of Immune and Epithelial Factors to Folliculogenesis , 1995, American journal of reproductive immunology.

[65]  T. Shows,et al.  EGR3, a novel member of the Egr family of genes encoding immediate-early transcription factors. , 1991, Oncogene.